Effectiveness Of Therapy In Patients Research Articles

Zastosowanie EEG Biofeedback/Neurofeedback w rehabilitacji psychiatrycznej

The aim of the systematic review was to evaluate the use of EEG Biofeedback/Neurofeedback in patients treated for mental disorders. The review covered publications analyzing influences and effects of therapy in patients receiving psychiatric treatment based on EEG Biofeedback/Neurofeedback. Selection of publications was made by searching PubMed and Scopus databases. 328 records concerning applications of the presented method were identified in total, including 84 records for patients diagnosed with mental disorders. The analysis of studies indicates that EEG Biofeedback/Neurofeedback is used for treatment of neurological, somatic and mental disorders. Its psychiatric applications for clinically diagnosed disorders include treatmentof depression, anorexia, dyslexia, dysgraphia, ADD, ADHD, schizophrenia, abuse of substances, neuroses, PTSD, and Alzheimer's disease. Research results imply that the neuromodulating effect of the therapy positively influences cognitive processes, mood, and anxiety levels. Positive effects of EEG Biofeedback confirm usefulness of this method as a main or auxiliary method in treatment of people with mental disorders. On the basis of conducted studies, it is worthwhile to consider inclusion of this method into the comprehensive neurorehabilitation activities.

Evaluation of Neural Therapy Effects in Patients with Lateral Epicondylitis: A Randomized Controlled Trial

Objectives: The purpose of the study is to explore neural therapy (NT) and the effect of it on pain and the functional status of patients with lateral epicondyl i tis (LE) and to determine whether clinical changes and demographic characteristics have any correl a tion. Materials and Methods: Forty-two patients with LE were randomly allocated into two groups; NT & control. The control group was given rest, non-steroidal anti-inflammatory drugs, stretching exercises and a wrist splint. The p a tients in the NT group received 8 sessions of NT. The visual analog scale (VAS), pain pressure threshold (via algometry) and Duruöz hand index (DHI) scores were noted before and at the end of the treatment in both groups. Results: All parameters improved in both groups. However, improvement of VAS, a l gometry and DHI scores were more obvious in the NT group. The clinical change and d e mographic features of the groups showed no correlation. Conclusion: NT is a safe and effective treatment method for treatment of p a tients with LE.

Combination therapeutic options in the treatment of the luteal phase deficiency

Luteal phase deficiency (LPD) is described as a condition of insufficient progesterone exposure to maintain a regular secretory endometrium and allow for normal embryo implantation and growth. There is evidence that both follicular and luteal phase abnormalities can result in LPD cycles. The aim of this randomized prospective noncomparative study is to evaluate the effectiveness of combination therapy in patients with LPD. This prospective study included 35 women of the reproductive age. They were diagnosed with the LPD with sonographically and laboratory-verified methods. The age of patients was 36 ± 0.46 years. The results of the study sonographically demonstrated an increase in the diameter of the corpus luteum from 1.36 ± 0.32 (initially) to 2.16 ± 0.21 mm after combination therapy. In addition, there was a statistically significant increase in the level of estrogens and progesterone in the corresponding phases of the menstrual cycle. Thus, the combination therapy for patients with LPD contributes to the recovery of cyclic events in the hypothalamic-pituitary-gonadal system, which determines the restoration of the endocrine function of the ovaries and promotes adequate secretory rearrangement of the endometrium in women of reproductive age.

The effect of Danshen extract on lipoprotein-associated phospholipase A2 levels in patients with stable angina pectoris: study protocol for a randomized controlled trial - the DOLPHIN study

BackgroundLipoprotein-associated phospholipase A2 (Lp-PLA2), a biomarker of oxidation and inflammation, has been associated with increased coronary artery disease risk. To date, very few studies have examined the Chinese herbal drug Danshen or its extract on Lp-PLA2 in patients with stable angina pectoris. In this study, we aim to investigate the effect of Danshen extract on Lp-PLA2 level in patients with stable angina.Methods/designThis is a randomized, single-blind, placebo-controlled, adaptive clinical trial. A total of 156 patients meeting the eligibility criteria will be randomly assigned to either the Danshen extract (DanshenDuofensuanyan injection and Danshen drop spill) group or the placebo group in a 1:1 ratio. Participants will then undergo treatment with DanshenDuofensuanyan injection or placebo (glucose) during hospitalization, followed by open-label Danshen drop spill (30 pills/day) in Danshen extract group for 60 days after discharge. Because this is an adaptive trial, two interim analyses are prospectively planned. These will be performed after one-third and two-thirds of the patients, respectively, have completed the trial. On the basis of the results of these interim analyses, a data monitoring committee will determine how to modify aspects of the study without undermining the validity and integrity of the trial. The primary outcome measure is the serum level of Lp-PLA2 in the Danshen extract group and the placebo group. The secondary outcomes include the proportion of patients who show a clinically significant change, which is defined as at least a 20-point improvement in angina frequency score on the Seattle Angina Questionnaire and the carotid intima-media thickness, which will be measured using ultrasound. Other secondary efficacy and safety outcomes will also be assessed.DiscussionThis study will provide evidence that Danshen extract is beneficial for stable angina and may establish a possible mechanism of Danshen treatment effects on cardiovascular disease. This study may also validate an objective blood test (LP-PLA2 level) for assessing the effectiveness of Danshen therapy in patients with stable angina pectoris.Trial registrationClinicalTrials.gov, NCT02870764. Registered on 13 August 2016.

AMETYST – Results of an Observational Phase IV Clinical Study Evaluating the Effect of Intramuscular Interferon Beta-1a Therapy in Patients with Clinically Isolated Syndrome or Clinically Definite Multiple Sclerosis

AMETYST – Results of an Observational Phase IV Clinical Study Evaluating the Effect of Intramuscular Interferon Beta-1a Therapy in Patients with Clinically Isolated Syndrome or Clinically Definite Multiple Sclerosis

Short-term histopathological effects of dienogest therapy on ovarian endometriomas: in vivo, nonrandomized, controlled trial

Ovarian endometriosis is a common gynecological disorder. To date, progestins are recommended as the first-line medical treatment for symptomatic ovarian endometriosis. The aim of this study was to evaluate the main histopathological effects of short-term dienogest therapy in patients with ovarian endometriomas scheduled for surgery. A prospective, nonrandomized controlled trial, including 70 symptomatic women with single ovarian endometriotic cyst (diameter between 30–50 mm) was conducted. Women scheduled for surgery were divided into two groups, depending on the treatment established at enrollment: 36 women received progestin therapy with dienogest (P group) and 34 women received no therapy (C group). At histopathological examination necrosis, inflammation, decidualization, glandular atrophy and angiogenesis were blindly evaluated. At tissue level, decidualization was significantly more frequent in P group compared to C group (p = .001). A nonsignificant tendency (p = .29) towards a slight decreased inflammation in P group was found. No significant differences were observed between the two groups in terms of necrosis, glandular atrophy and angiogenesis. The study suggests that high decidualization rate and the tendency to reduced inflammatory reaction in the short-term administration of dienogest might contribute to its therapeutic efficacy.

Serum Macrophage Migration Inhibitory Factor as a Biomarker of Active Pulmonary Tuberculosis.

BackgroundMacrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine with chemokine-like functions, has been shown to play a central role in several acute and chronic inflammatory diseases. However, limited information is available regarding the use of MIF as an inflammatory pathway marker in patients with tuberculosis. This study aimed to investigate the association of MIF with IFN-γ and TNF-α in active pulmonary tuberculosis (APTB) following anti-tuberculosis treatment.MethodsThe MIF, TNF-α, and IFN-γ serum levels were determined in 47 patients with APTB by cytokine-specific ELISA at four phases: prior to anti-tuberculosis drug treatment (baseline), and following 2, 4, and 6 months of treatment. In addition, we measured the MIF, TNF-α, and IFN-γ serum levels in 50 health controls.ResultsMIF serum levels were significantly elevated (P<0.05) in patients with APTB prior to treatment compared with that in control subjects, and TNF-α ≥449.7 pg/mL was associated with high MIF levels (≥13.1 ng/mL). MIF levels were significantly reduced (P<0.01) following 2, 4, and 6 months of treatment, with variations in TNF-α and IFN-γ serum levels. MIF levels were positively correlated with the paired TNF-α level at baseline (r=0.1103, P=0.0316) and following 6 months of treatment (r=0.09569, P=0.0364).ConclusionsA reduction in the MIF serum levels in patients with APTB following anti-tuberculosis treatment may positively affect host immune protection against Mycobacterium tuberculosis infection. Thus, serum MIF levels may constitute a useful marker for assessing therapy effectiveness in patients with APTB.

ОСОБЛИВОСТІ БІОЦЕНОЗУ ТА ФУНКЦІОНАЛЬНОЇ АКТИВНОСТІ ВАГІНАЛЬНОГО ЕПІТЕЛІЮ ПРИ МІСЦЕВОМУ ЛІКУВАННІ НЕСПЕЦИФІЧНОГО ВАГІНІТУ

Мета дослідження – оцінити клінічну та мікробіологічну ефективність і безпечність застосування препарату «Кломезол» у лікуванні неспецифічного вагініту.Матеріали та методи. Для вирішення поставленого завдання проведено обстеження і лікування 60 жінок репродуктивного віку з діагнозом аеробного вагініту. Проведено оцінку клінічної та мікробіологічної ефективності терапії у пацієнток з аеробним вагінітом. Вивчено терміни зникнення об’єктивних і суб’єктивних симптомів запального процесу, особливості функціональної активності епітелію піхви, вплив препарату на стан нормальної мікрофлори піхви. Дослідження проведено відповідно до міжнародних нормативів і правил GCP.Результати дослідження та їх обговорення. У результаті проведеного дослідження було встановлено, що комбінований препарат «Кломезол» у вигляді вагінальних свічок є ефективним по відношенню до умовно-патогенних мікроорганізмів – збудників аеробного вагініту і є препаратом вибору для лікування бактеріального вагінозу та аеробного вагініту. Кломезол не здійснює імуносупресивного впливу на епітелій піхви, завдяки цьому відновлення функціональної активності епітелію після лікування кломезолом відбувається швидше, ніж після лікування тержинаном. Відмічено покращення якості життя пацієнток після лікування.Висновки. Відмічена висока ефективність комбінованого препарату «Кломезол» по відношенню до широкого спектра мікрофлори, доведена висока терапевтична активність та безпечність у використанні у пацієнток з аеробними вагінітами. Кломезол добре переноситься та не викликає резистентності мікрофлори. Препарат може використовуватись у ІІ і ІІІ триместрах вагітності.

Combined therapy effectiveness in patients with mild cognitive dysfunction

Combined therapy effectiveness in patients with mild cognitive dysfunction

Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells

Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) are one of the major causes of blindness caused by neo-vascular changes in the retina. Intravitreal anti-VEGF injections are widely used in the treatment of wet-AMD and PDR. A significant percentage of treated patients have complications of repeated injections. Resveratrol (RES) is a polyphenol phytoalexin with anti-oxidative, anti-inflammatory and anti-proliferative properties. Hence, we hypothesized that if RES is used in combination with bevacizumab (BEV, anti-VEGF), it could reverse the adverse effects that precipitate fibrotic changes, drusen formation, tractional retinal detachment and so on. Human retinal pigment epithelial cells were treated with various combinations of BEV and RES. There was partial reduction in secreted VEGF levels compared to untreated controls. Epithelial-mesenchymal transition was lower in BEV + RES treated cultures compared to BEV treated cultures. The proliferation status was similar in BEV + RES as well as BEV treated cultures both groups. Phagocytosis was enhanced in the presence of BEV + RES compared to BEV. Furthermore, we observed that notch signaling was involved in reversing the adverse effects of BEV. This study paves way for a combinatorial strategy to treat as well as prevent adverse effects of therapy in patients with wet AMD and PDR.

Abstract 1842: Breast cancer brain metastasis (BCBM) model for determination of therapeutic brain penetration

Abstract Purpose Brain metastases are presenting an increasing problem in the clinic, and especially in treatment of patients with human epidermal growth factor receptor-2 (HER2)-amplified breast cancer. Although extracranial metastases respond well to HER2 inhibitors, human clinical data shows brain metastases hide behind an intact blood-brain barrier (BBB) and are largely untreatable. Many current preclinical models lack this barrier integrity, limiting their utility in understanding delivery of drugs to the brain. We present here the development of a new model suitable for evaluating therapeutic brain penetration in addition to efficacy. Experimental procedures Human HER2-amplified BT-474 breast cancer cells were inoculated intravenously (tail vein) in female Rag2-/-;Il2rg-/- mice (2 million cells/mouse) to induce multiorgan metastasis. Formation of metastatic brain lesions was monitored by magnetic resonance imaging (MRI). For comparison, BT-474 cells were inoculated intracranially for direct brain tumor implantation (50,000 cells/mouse). Response to a suite of HER2-targeted therapies known not to appreciably cross an intact BBB (trastuzumab, lapatinib, etc.) was monitored by MRI for both metastatic and implanted brain tumors. Mice were sacrificed following signs of prolonged distress or loss of &amp;gt;20% body weight. Organs were collected for standard histological and immunohistochemical analysis, as well as for CLARITY tissue clearing and large-scale 3D macromolecule mapping. Results Intravenous inoculation of BT-474 cells into Rag2-/-;Il2rg-/- mice consistently reproduced the full metastatic profile seen in humans, with metastases in the lung, bone, liver, ovary, lymph, and brain tissues. Brain metastases were detected in &amp;gt;90% of mice inoculated intravenously. Histological analysis of metastatic brain tumors showed different morphologies and invasive characteristics compared to those intracranially implanted. Additional differences in vasculature between metastatic and implanted brain tumors were identified by CLARITY. Importantly, HER2-targeted therapy markedly delayed progression of implanted brain tumors, but failed to control metastatic brain tumor growth, recapitulating the clinical situation. Conclusions These data, together with ongoing efforts to further characterize therapeutic transport to these brain tumors, suggest that intracranial inoculation disrupts the BBB and creates artificial routes for therapeutics to reach implanted brain lesions, resulting in anomalous tumor response. In contrast, this new metastatic model reproduces the discordant effects of HER2-targeted therapy in patients, and offers a platform for studying the efficiency of therapeutic delivery across an intact BBB as well as antitumor activity, both of which are critical to effective clinical translation. Citation Format: Emily A. Wyatt, Mark E. Davis. Breast cancer brain metastasis (BCBM) model for determination of therapeutic brain penetration [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1842. doi:10.1158/1538-7445.AM2017-1842

The effect of combined therapy on the properties of the vessel wall in patients at high risk of cardiovascular complications

Introduction. The evaluation of therapy effectiveness in patients at high risk of cardiovascular complications includes the evaluation of target organs condition. A complex approach means follow-up control of laboratory and instrumental data. Materials and methods. The study included 113 patients with hypertension and nonstenotic atherosclerosis of brachiocephalic arteries. All the patients received antihypertensive therapy and some received hypolipidemic drugs. Cholesterol and low density lipoproteins (LDL) levels, brachial and central blood pressure (BP), brachial-ankle and carotid-femoral pulse wave velocity (baPWV and cfPWV, respectively), augmentation index (AI) of fibrosis markers (C-terminal telopeptide from collagen I (CITP) and C-terminal terminal propeptide of pro-collagen I (PINP) were assessed at baseline, after 6 months and 12 months of treatment with fixed combination of amlodipine, lisinopril and rosuvastatin. Results. The conducted therapy was followed by lowering the LDL levels from 3.9 (3.1; 4.6) to 2 (1.8; 2.3) mmol/L (p

P439Does restoration of sinus rhythm influence the effectiveness of cardiac resynchronization therapy in patients with severe heart failure and permanent atrial fibrillation?

P439Does restoration of sinus rhythm influence the effectiveness of cardiac resynchronization therapy in patients with severe heart failure and permanent atrial fibrillation?

Prognostic factors and effects of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.

e15703 Background: The aim of this study is to identify prognostic factors and effects of adjuvant therapy for patients with ampullary adenocarcinoma who had pancreatoduodenectomy. Methods: A cohort of 123 consecutive patients underwent pancreatoduodenectomy for ampullary adenocarcinoma from January 1, 2006, through August 31, 2016 at Mayo Clinic in Rochester, MN. Only patients with ampullary carcinoma by pathology review were included and were histologically classified as pancreaticobiliary or intestinal subtypes. Median follow-up duration was 41.0 months. Patient survival and its correlation with patient and tumor variables were tested by univariate and multivariate analysis. Results: Pancreatoduodenectomy was curative-intent in 120 out of 123 patients. All 123 patients underwent radical surgery, 32 patients (26.0%) had laparoscopic pancreatoduodenectomy. Among 123 patients, there were 76 men (61.8%).Median age at diagnosis was 67.2 years. 54 patients (45%) without metastatic disease upon surgery had adjuvant therapy (35 patients had chemotherapy only while 19 patient also had radiation). Median overall survival (OS) was 91.8 months. Poor performance status at disease diagnosis (ECOG &gt; = 1), old age ( &gt; = 70 years), primary tumor infiltration (T), lymph node metastasis (N), and advanced disease stage (TNM) had a significant negative impact on survival (p &lt; 0.05 by univariate analysis). Gender, diabetes at disease diagnosis, laparoscopic surgery approach, number of lymph nodes removed, number of positive lymph nodes, and tumor size did not influence survival. In multivariate analysis, ECOG score &gt; = 1, adjuvant treatment, primary tumor infiltration (T) and lymph node metastasis (N) remained statistically significant. Adjuvant therapy was independently associated with improved disease free survival (P = 0.0388) and overall survival (p = 0.030) for patients with advanced disease (stage IIB and above). Conclusions: Poor performance status and advanced disease stage are associated with decreased survival in patients with ampullary adenocarcinoma. Patients with advanced disease should be considered for adjuvant chemotherapy.

Efficacy of Thrombolytic Therapy in Treatment of Patients with Ischemic Stroke

The purpose: to evaluate the effectiveness of thrombolytic therapy in patients with ischemic stroke according to radiological methods.Materials and methods. The study included 60 people who were divided into two groups. The main group included 34 (56.7%) patients with ischemic stroke (20 men and 14 women) aged 22 to 78 years (mean age 62 ± 8.6 years) who were treated in Republican research center of emergency medical care. The control group consisted of 26 (43.3%) patients to estimate the parameters of normeperidine in the middle cerebral artery (MCA): the maximum blood flow velocity, linear blood flow velocity, index Gosling (PI) and coefficient overshoot (KO). Evaluation of patients included: assessment of nevrostatus according NIHSS scale, computered tomograhy of brain to exclude hemorrhagic stroke, transcranial and extracranial arteries Duplex scanning, digital subtraction angiography. Thrombolysis was performed to all patients of main group with ischemic stroke: systemic thrombolysis with streptokinase – in 17 (50%) cases, selective thrombolysis of Actilyse – 17 (50%). Thrombolysis was performed in a period from 90 minutes to 4 hours after the manifestation of symptoms. Results. Significant positive changes were observed in 22 (64.7%) patients. Asymptomatic hemorrhagic transformation of ischemic lesion was observed in 4 (11.7%). In acute occlusion of the internal carotid artery recanalization was registered only in 11.7% of cases, while the M1 MCA occlusion segment – at 52.9%. Transcranial Doppler is manifested by registration of hyperperfusion flow after thrombolysis in the presence of residual flow to thrombolysis. Re-occlusion was observed in 2 (5.8%) patients. In these cases, before and after thrombolysis TCD fixed flow hypoperfusion. Mortality was 14.7%.Conclusions. Thrombolytic therapy is effective treatment for ischemic stroke, especially in the delivery of the patient to a hospital for the first 2 hours after the manifestation of clinical symptoms. The marker of effectiveness thrombolysis is registration on the CMA normoperfusion or hyperperfusion pattern. Good functional outcome marked when a patient achieved result ≤2 points on the mRS. Asymptomatic hemorrhagic transformation can also be considered as a marker of effective thrombolysis. The combination of a CT scan of the brain with transcranial Doppler allows to assess not only the size of the lesion of the brain, but also to investigate the nature of cerebral hemodynamics. Further development of a set of measures designed to raise awareness among the population and general practitioners about the symptoms of stroke and its effective treatment in the case of delivery of the patient to a specialized hospital in which is possible to conduct thrombolysis.

Investigation on relationships between reduction of cisplatin and anticancer effects in patients with bladder cancer.

306 Background: Cisplatin (CDDP)-based chemotherapy is recognized as standard treatment for patients with advanced urothelial cancer (UC). In patients having lowered renal function, dosage of CDDP must be decreased for prevention of adverse events. However, relationship between reduction of CDDP and anti-cancer effects is not fully understood. The main aim is to clarify the influence of pathological anti-cancer effects by decreasing of CDDP in muscle invasive bladder cancer (MIBC). In addition, anti-cancer effects of radiation therapy in patients with decreased dosage of CDDP are also investigated. Methods: One hundred thirty three patients with MIBC selected CDDP-based intra-arterial chemotherapy. Biopsy was performed before intra-arterial chemotherapy, and then complete resection by trans-urethral resection was done after the therapy. Decreased dosage was defined as reduction ratio is over 20%, and 34 patients were judged as decreased dosage group. Two courses of chemotherapy with CDDP (70 mg/m2) and doxorubicin (30 mg/m2 / epirubicin (30 mg/m2) were administered, and each course of chemotherapy was repeated approximately every 4 weeks. In 78 patients (58.6%), radiation therapy (total 40 – 60 Gy) began the day after chemotherapy administration. Results: The rate of down-stage after the chemotherapy in standard dosage group (63 of 99, 63.6%) was significantly higher (P=0.046) than that in decreased dosage one (15 of 35, 50.5%). In regard to pathological complete response (p-CR), patients with p-CR in decreased dosage group (n=9, 26.5%) were significantly lower (P=0.015) than those in standard dosage one (n=50, 50.5%). When similar analysis were performed in patients without radiation therapy, rate of p-CR in decreased dosage group was just 10.0%. On the other hand, p-CR was achieved in 33.3% in patients with radiotherapy of decreased dosage group. Conclusions: Reduction of CDDP may decrease its anti-cancer effects in patients with MIBC. On the other hand, combination of radiotherapy can increase the rate of p-CR in patients who treated with decreased dosage of CDDP. We believe our results are useful for discussion on treatment strategies in UC patients having lowered renal function.

Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cells

Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cells

THE EXPERIENCE OF TREATMENT OF PATIENTS WITH ULCER DISEASE WITH ASSOCIATED CHRONIC DUODENAL INSUFFICIENCY

Objective: study of the efficacy of tiotyprid hydrochloride in the complex therapy of patients with gastric ulcer and duodenal ulcer with concomitant chronic duodenal insufficiency. Materials and methods. Verification of ulcer disease was performed clinically and by fibrogastroduodenoscopic researches. In determination of chronic duodenal insufficiency there were used data of contrast duodenography and cavitary manometry. We have studied motor performance of the stomach and gastroduodenal ulcer with a help of peripheral electrogastrograph ЭГГ-4М. The protective properties of gastric mucus were determined by using the Sialo Test reagent kit. Gastrin, cortisol, insulin in the blood serum were studied with a help of method ELISA. Results of the study. We have carry out complex examination of 104 patients with ulcer disease which were divided into 2 groups. The 1st group consisting of 52 patients with gastric ulcer with concomitant HDN was given in the complex therapy prokinetic taupoide hydrochloride in dose of 50 mg 3 times a day for 2 weeks. The 2st group in the number of 52 patients with gastric ulcer with concomitant HDN received only standard anti-ulcer therapy. With a comparative evaluation of the effectiveness of therapy in patients 1 gr. established, in addition to the positive dynamics of clinical symptoms, a distinct improvement in the motor activity of stomach and duodenum, the restoration of the gatekeeper’s closure function, and the enhancement of protective and protective properties of gastric mucus. The scarring of ulcer was revealed in 97,4 ± 1,8% of patients of 1 group, in 87,1 ± 0,41% cases in the stage of mature “white rumen” (S2). In patients 2 group the scarring of the ulcer occurred in 92.1 ± 3.1% of cases, but in 41 ± 4.3% of cases, ulceration was substandard, that is, in the “red scar” stage (S1). Conclusion. The using of prokinete ticopride hydrochloride in the complex treatment of gastric ulcer with concomitant HDN is pathogenetically substantiated and clinically effective.

Влияние комбинированной терапии на состояние сосудистой стенки у больных высокого сердечно-сосудистого риска

Introduction. The evaluation of therapy effectiveness in patients at high risk of cardiovascular complications includes the evaluation of target organs condition. A complex approach means follow-up control of laboratory and instrumental data. Materials and methods. The study included 113 patients with hypertension and nonstenotic atherosclerosis of brachiocephalic arteries. All the patients received antihypertensive therapy and some received hypolipidemic drugs. Cholesterol and low density lipoproteins (LDL) levels, brachial and central blood pressure (BP), brachial-ankle and carotid-femoral pulse wave velocity (baPWV and cfPWV, respectively), augmentation index (AI) of fibrosis markers (C-terminal telopeptide from collagen I (CITP) and C-terminal terminal propeptide of pro-collagen I (PINP) were assessed at baseline, after 6 months and 12 months of treatment with fixed combination of amlodipine, lisinopril and rosuvastatin. Results. The conducted therapy was followed by lowering the LDL levels from 3.9 (3.1; 4.6) to 2 (1.8; 2.3) mmol/L (p<0.01), brachial systolic and diastolic BP levels from 127 (116; 139) to 123 (115; 131) mm Hg (p<0.01) and from 79 (72; 89) to 75 (70; 83) mm Hg (p<0.01) respectively, central systolic and diastolic BP levels from 126 (112; 137) to 120 (110; 124) mm Hg (p<0.01) and from 80 (75; 87) to 76 (70; 81) mm Hg (p<0.01) respectively; by decreasing arterial stiffness: baPWV from 13.6 (12.5; 15.9) to 12.9 (11.8; 14.3) m/s (p<0.01) and cfPWV from 11 (9; 12.2) to 9.4 (8.4; 10.2) m/s (p<0.01), AI decreased from 31 (25; 35) to 26 (21; 32); p<0.05. The arterial stiffness index calculated without BP levels (cardio-ankle vascular index) decreased from 7.2 (6.6; 8.3) to 7.0 (6.6; 7.9) m/s (p<0.05). Treatment with Ekvamer® resulted in PINP levels decreasing from 49.8 (33; 67) to 35 (21; 52) mg/dL (p<0.05) and CITP - from 0.44 (0.24-0.6) to 0.3 (0.18-0.46) mg/dL (p<0.05). No difference between initial and final PINP/CITP levels was observed. The dynamics of PINP levels was associated with aortal stiffness dynamics, cfPWV (r=0.5; p<0.05). Conclusion. Treatment with fixed combination of amlodipine, lisinopril and rosuvastatin resulted in reaching target levels of LDL, brachial and central BP, and arterial stiffness decrease in patients at high risk of cardiovascular complications. The cfPWV dynamics was inter-related with collagen synthesis marker PINP levels.

Electromyographic analysis of constraint-induced movement therapy effects in patients after stroke in chronic course.

[Purpose] The purpose is to analyze the effects of Constraint-induced Movement Therapy in post stroke patients in chronic course. [Subjects and Methods] This is a Quasi-experiment study and the adopted protocol consisted of a three-hour therapy for ten consecutive working days applied to a constraint intact upper limb. Surface Electromyography, Motor Activity Log, Wolf Motor Function Test and Functional Independence Measure were used for evaluating the experiment. [Results] The individuals showed reduction in the degree of spasticity, confirmed by Surface Electromyography. In relation to Motor Activity Log this study showed an increase in amount and in quality of the paretic upper limb movement. The Wolf Motor Function Test showed reduction in the average time to perform the tasks and a functional improvement was identified through the Functional Independence Measure. [Conclusion] Constraint Induced Movement Therapy proved to be a relevant method to improve motor function in chronic hemiparesis post stroke reducing the spasticity, maximizing and improving the use of committed upper limb.